三生国健(688336) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥160,512,362, representing a year-on-year increase of 3.34%[7] - The net profit attributable to shareholders was ¥349,316, while the net profit excluding non-recurring gains and losses was -¥5,364,803[7] - The company anticipates a decline in Q2 2022 sales revenue compared to the same period last year due to ongoing pandemic control measures[19] - The company reported a total cash inflow from investment activities of 1,405,579,516.49 CNY, compared to 813,436,014.14 CNY in Q1 2021[36] - The total comprehensive income for Q1 2022 was a loss of CNY 7,326,913.26, compared to a loss of CNY 35,394,735.67 in the same period last year[32] Cash Flow - The net cash flow from operating activities was ¥80,208,154, showing an increase compared to the same period last year due to improved sales collection[9] - Cash inflow from operating activities totaled 292,032,841.38 CNY, an increase of 63.6% from 178,438,646.42 CNY in Q1 2021[33] - The company reported a net cash flow from operating activities of 80,208,154.46 CNY, a significant improvement from -83,420,036.71 CNY in the previous year[33] - The cash and cash equivalents at the end of the period amounted to 266,361,087.32 CNY, compared to 1,337,200,139.04 CNY at the end of the previous period[47] Research and Development - Total R&D investment amounted to ¥65,255,796, a decrease of 34.10% year-on-year, attributed to pandemic control measures affecting some R&D activities[9] - R&D expenses accounted for 40.65% of operating revenue, a decrease of 23.09 percentage points compared to the previous year[9] - Research and development expenses were CNY 64,161,070, a decrease of 33.5% compared to CNY 96,389,040 in Q1 2021[28] - Research and development expenses for Q1 2022 were RMB 49,649,792.18, down from RMB 84,779,508.42 in Q1 2021, indicating a strategic reduction in R&D spending[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,866,668,728.58, a decrease of 0.45% from the end of the previous year[9] - Total liabilities decreased to CNY 330,663,188.54 from CNY 349,731,365.38, reflecting a reduction of approximately 5.5%[27] - The company's total equity increased to RMB 4,809,911,170.63 in Q1 2022 from RMB 4,802,297,754.45 in Q1 2021, reflecting a positive trend in shareholder value[44] Shareholder Information - The company reported a total of 12,598 common shareholders at the end of the reporting period[13] - The largest shareholder, Fujian Pharmaceutical Co., Ltd., held 35.95% of the shares[13] Operational Costs - Total operating costs decreased to CNY 175,560,381, down 18.7% from CNY 216,036,586 in the previous year[28] - The company reported a significant reduction in sales expenses to CNY 50,695,184.53 from CNY 77,422,576.11, a decrease of 34.4%[28] - The company recorded a decrease in sales expenses to RMB 50,694,508.68 in Q1 2022 from RMB 77,418,945.53 in Q1 2021, indicating improved cost management[44] Legal and Regulatory Risks - The company is exposed to legal risks due to its operations in the highly regulated biopharmaceutical industry, which may affect its financial performance[19] - The company is implementing new accounting standards starting from 2022, which may affect financial reporting[47] Miscellaneous - The company did not conduct an audit for the financial statements of this quarter[7] - The report was released on April 27, 2022, indicating the company's commitment to transparency and timely disclosure of financial information[47]